This case-based program explores the missed opportunities in CKD detection and treatment in a patient with type 2 diabetes. Drs. Agarwal and Cos emphasize the role of primary care physicians in annual UACR screening, which can reveal kidney injury long before symptoms occur. With new evidence from the CONFIDENCE and other trials, the discussion highlights the benefits and safety of early combination therapy with finerenone and SGLT2i, and GLP-1 receptor agonists. Practical strategies are shared to support primary care teams in integrating these therapies and reducing long-term cardio-kidney-metabolic risk.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.

This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical implications of PD-L1 expression. Case-based dialogues highlight diagnostic approaches, treatment planning, and toxicity management across disease stages. The program underscores the importance of coordinated care involving oncologists, nurse practitioners, and pathologists to optimize outcomes.